This is a preprint.
The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors
- PMID: 39229179
- PMCID: PMC11370389
- DOI: 10.1101/2024.08.17.607802
The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors
Update in
-
The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors.Sci Rep. 2025 Mar 24;15(1):10128. doi: 10.1038/s41598-025-94517-w. Sci Rep. 2025. PMID: 40128216 Free PMC article.
Abstract
Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive sarcoma that may be seen in patients with neurofibromatosis type 1 (NF1) or occur sporadically. While surgery is the primary treatment for localized MPNST with a 61.9% overall survival rate, metastatic disease is often fatal due to resistance to systemic therapies which underscores the urgent need for effective treatments. MPNSTs frequently harbor inactivating driver mutations in the PRC2 epigenetic repressor complex suggesting epigenetic therapies may represent a specific vulnerability in these tumors. Here, we investigate the role of the LSD1-HDAC1-CoREST (LHC) repressor complex in mediating MPNST tumor growth and progression. Our findings demonstrate that the LHC small molecule inhibitor, corin, induces apoptosis and significantly inhibits proliferation in MPNST cells. Transcriptomic analysis of corin-treated MPNST cells demonstrates specific increases in genes associated with axonogenesis and neuronal differentiation as well as altered extracellular matrix; additionally, corin treatment is shown to inhibit MPNST invasion in vitro. These results underscore the critical role of the LHC complex in facilitating MPNST growth and progression and suggest that targeting the LHC complex represents a promising therapeutic approach for this aggressive malignancy.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous